Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GlaxoSmithKline Pharma Net Up 6 Percent (India)

This article was originally published in PharmAsia News

Executive Summary

GlaxoSmithKline's India division increased its net profit by 6 percent during second quarter 2007 compared to last year. The Indian division is developing four new anti-diabetic products, and this year has successfully launched two such products, Windia and Windamet. GSK's total sales fell by 2.1 percent, mostly due to the sale of Virbac Animal Health in 2006, one reason its operations efficacy and net profit increased in second quarter 2007. The company also is selling Qualigens Fine Chemicals to India-based Thermo Electron LLS India for Rs 240 crore. (Click here for more

You may also be interested in...



Austria’s Apeiron To Attack COVID-19 At Its Entry Point

Apeiron Biologics has fashioned a recombinant version of the enzyme to which SARS-CoV-2 is thought to bind, and with governmental help has started a Phase II study in Austria, Germany and Denmark. 
 
 
 

 

Executives On The Move: BMS Taps Barclays Exec For Strategy Spot, Epizyme Selects Science Chief And A Board Election At ADC Therapeutics

Bristol-Myers Squibb taps Barclays chair of global life sciences as it EVP, strategy and business development, and cancer therapeutics firm Epizyme Inc. selects a chief scientific officer. At ADC Therapeutics, an oncology drug development company, a new chairman is elected.

EU Regulatory Roundup, March 2020: MDR Delay And Unprecedented COVID-19 Measures

Non-CE-marked products on the EU market, virtual notified body audits, free standards and the Commission bid to pause the MDR. March has seen unprecedented developments as COVID-19 has railroaded through the sector decimating regulatory rules and plans.

UsernamePublicRestriction

Register

SC066393

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel